Pub Date : 2025-05-01DOI: 10.1016/j.reumae.2025.501872
Clementina López-Medina , Lucía Otero-Varela , Fernando Sánchez-Alonso , Vega Jovaní , Lorena Expósito-Pérez , Sheila Melchor-Díaz , Yanira Pérez-Vera , Paula Pretel-Ruiz , Javier Manero , Antonio Mera-Varela , Lourdes Mateo , Dolores Ruiz-Montesino , José Andrés Lorenzo-Martín , Teresa Pedraz-Penalva , Isabel Castrejón
Introduction
Ixekizumab (IXE) is a selective interleukin 17A (IL-17A) monoclonal antibody approved for the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). Limited real-world data are available on its retention rate and effectiveness. The objective of this study was to assess the one-year retention rate of IXE in a real-world cohort of patients with axSpA and PsA and to identify potential predictive factors for drug retention.
Method
Prospective and observational study derived from BIOBADASER 3.0, a multicenter registry of advanced therapies including patients who have ever received IXE for PsA or axSpA. The one-year retention rate of the treatment in both diseases was evaluated using Kaplan–Meier curves and multivariable Cox regressions.
Results
A total of 335 patients ever exposed to IXE were included (PsA = 250; axSpA = 85). IXE was used as first-line treatment only in 5.3% of patients, and after TNFi in 94.7% of patients. In axSpA and PsA, drug survival at 12 months was 69.5% (95% CI 64.0–74.3), slightly higher in PsA (71.3% (95% CI 65.0–75.6)) versus axSpA (63.8% (95% CI 51.5–73.7)). The multivariable Cox regression models showed that female sex and longer disease duration were factors associated with IXE withdrawal in the whole population, while concomitant use of methotrexate reduced the risk of discontinuation.
Conclusions
In this real-world study, IXE showed an acceptable retention rate in patients with PsA and axSpA after one year of follow-up. Female sex and longer disease duration were associated with risk of withdrawal.
ixekizumab （ixxe）是一种选择性白细胞介素17A （IL-17A）单克隆抗体，被批准用于治疗银屑病关节炎（PsA）和轴性脊柱炎（axSpA）。关于其留存率和有效性的真实数据有限。本研究的目的是评估现实世界axSpA和PsA患者中IXE的1年保留率，并确定药物保留率的潜在预测因素。方法：前瞻性和观察性研究来源于BIOBADASER 3.0，这是一个多中心的先进治疗注册，包括曾因PsA或axSpA接受IXE治疗的患者。采用Kaplan-Meier曲线和多变量Cox回归评估两种疾病治疗的1年保留率。结果共纳入335例暴露于IXE的患者(PsA = 250；axSpA = 85)。仅5.3%的患者使用IXE作为一线治疗，而在TNFi后使用IXE的患者比例为94.7%。在axSpA和PsA中，12个月的药物生存率为69.5% (95% CI 64.0-74.3), PsA (71.3% （95% CI 65.0-75.6）略高于axSpA （63.8% (95% CI 51.5-73.7)）。多变量Cox回归模型显示，在整个人群中，女性和较长的病程是IXE停药的相关因素，而同时使用甲氨蝶呤降低了停药的风险。在这项现实世界的研究中，IXE在PsA和axSpA患者中随访1年后显示出可接受的保留率。女性和较长的疾病持续时间与停药风险相关。
{"title":"One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: Real-world data from the BIOBADASER registry","authors":"Clementina López-Medina , Lucía Otero-Varela , Fernando Sánchez-Alonso , Vega Jovaní , Lorena Expósito-Pérez , Sheila Melchor-Díaz , Yanira Pérez-Vera , Paula Pretel-Ruiz , Javier Manero , Antonio Mera-Varela , Lourdes Mateo , Dolores Ruiz-Montesino , José Andrés Lorenzo-Martín , Teresa Pedraz-Penalva , Isabel Castrejón","doi":"10.1016/j.reumae.2025.501872","DOIUrl":"10.1016/j.reumae.2025.501872","url":null,"abstract":"<div><h3>Introduction</h3><div>Ixekizumab (IXE) is a selective interleukin 17A (IL-17A) monoclonal antibody approved for the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). Limited real-world data are available on its retention rate and effectiveness. The objective of this study was to assess the one-year retention rate of IXE in a real-world cohort of patients with axSpA and PsA and to identify potential predictive factors for drug retention.</div></div><div><h3>Method</h3><div>Prospective and observational study derived from BIOBADASER 3.0, a multicenter registry of advanced therapies including patients who have ever received IXE for PsA or axSpA. The one-year retention rate of the treatment in both diseases was evaluated using Kaplan–Meier curves and multivariable Cox regressions.</div></div><div><h3>Results</h3><div>A total of 335 patients ever exposed to IXE were included (PsA<!--> <!-->=<!--> <!-->250; axSpA<!--> <!-->=<!--> <!-->85). IXE was used as first-line treatment only in 5.3% of patients, and after TNFi in 94.7% of patients. In axSpA and PsA, drug survival at 12 months was 69.5% (95% CI 64.0–74.3), slightly higher in PsA (71.3% (95% CI 65.0–75.6)) versus axSpA (63.8% (95% CI 51.5–73.7)). The multivariable Cox regression models showed that female sex and longer disease duration were factors associated with IXE withdrawal in the whole population, while concomitant use of methotrexate reduced the risk of discontinuation.</div></div><div><h3>Conclusions</h3><div>In this real-world study, IXE showed an acceptable retention rate in patients with PsA and axSpA after one year of follow-up. Female sex and longer disease duration were associated with risk of withdrawal.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 5","pages":"Article 501872"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144563657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01DOI: 10.1016/j.reumae.2025.501897
Aurora González Murcia , Isabel Valencia Ramírez , Teresa Catalina Plaza Aguado , José Antonio González Ferrández
We present the case of a 42-year-old male patient who was admitted for the study of axial and pelvic girdle pain, being diagnosed with hypophosphatemic osteomalacia secondary to a mesenchymal tumour after ruling out other causes of osteomalacia.
{"title":"Hypophosphatemic osteomalacia secondary to mesenchymal tumor","authors":"Aurora González Murcia , Isabel Valencia Ramírez , Teresa Catalina Plaza Aguado , José Antonio González Ferrández","doi":"10.1016/j.reumae.2025.501897","DOIUrl":"10.1016/j.reumae.2025.501897","url":null,"abstract":"<div><div>We present the case of a 42-year-old male patient who was admitted for the study of axial and pelvic girdle pain, being diagnosed with hypophosphatemic osteomalacia secondary to a mesenchymal tumour after ruling out other causes of osteomalacia.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 5","pages":"Article 501897"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144532171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01DOI: 10.1016/j.reumae.2025.501893
Hasan Huseyin Gokpinar , Cihan Caner Aksoy , Muhammed Fatih Ozdemir , İsmail Saraçoğlu
Objective
The aim of this study was to examine anxiety, depression, pain centralization, and pain catastrophization in patients with fibromyalgia syndrome (FMS) and evaluate whether these factors are predictors of disease severity in FMS.
Patient and methods
Depression was assessed with the Beck Depression Inventory (BDI), anxiety with the Beck Anxiety Inventory (BAI), pain centralization with the Centrality of Pain Scale (COPS), pain catastrophization with the Pain Catastrophizing Scale (PCS), and FMS severity with the Fibromyalgia Impact Questionnaire (FIQ). Two separate hierarchical linear regression analyses were performed to determine whether there was a significant association between disease severity and the assessed psychosocial factors.
Results
The study was completed with a total of 48 FMS patients (mean age 49.54 ± 8.28 years). FIQ score was moderately correlated with COPS score (rSpearman = 0.670, p < 0.001) and PCS score (rSpearman = 0.663, p < 0.001). In the logistic regression model, COPS and PCS scores were significant predictors of FIQ score. The predictive variables explained 43.7% of the variation in FIQ score.
Conclusion
This study showed that pain centralization and catastrophization can be considered indicators of disease severity in FMS. The results suggest that routine assessment of pain centralization and pain catastrophizing behaviors in individuals with FMS is needed and that cognitive behavioral therapy approaches may be beneficial in reducing disease severity.
目的本研究旨在探讨纤维肌痛综合征（FMS）患者的焦虑、抑郁、疼痛集中和疼痛灾难化，并评估这些因素是否为FMS疾病严重程度的预测因素。患者和方法采用贝克抑郁量表（BDI）、贝克焦虑量表（BAI）、疼痛中心性量表（COPS）、疼痛灾难化量表（PCS）和纤维肌痛影响问卷（FIQ）分别对患者进行抑郁、焦虑、疼痛集中和FMS严重程度的评估。进行了两次单独的分层线性回归分析，以确定疾病严重程度与评估的社会心理因素之间是否存在显著关联。结果共48例FMS患者（平均年龄49.54±8.28岁）完成研究。FIQ评分与COPS评分呈正相关(rSpearman = 0.670, p <；0.001)和PCS评分(rSpearman = 0.663, p <；0.001)。在logistic回归模型中，COPS和PCS得分是FIQ得分的显著预测因子。预测变量解释了43.7%的FIQ得分变异。结论疼痛集中和巨化可作为FMS疾病严重程度的指标。结果表明，有必要对FMS患者的疼痛集中和疼痛灾难化行为进行常规评估，认知行为治疗方法可能有助于降低疾病严重程度。
{"title":"Do psychosocial factors predict disease severity in fibromyalgia syndrome?","authors":"Hasan Huseyin Gokpinar , Cihan Caner Aksoy , Muhammed Fatih Ozdemir , İsmail Saraçoğlu","doi":"10.1016/j.reumae.2025.501893","DOIUrl":"10.1016/j.reumae.2025.501893","url":null,"abstract":"<div><h3>Objective</h3><div>The aim of this study was to examine anxiety, depression, pain centralization, and pain catastrophization in patients with fibromyalgia syndrome (FMS) and evaluate whether these factors are predictors of disease severity in FMS.</div></div><div><h3>Patient and methods</h3><div>Depression was assessed with the Beck Depression Inventory (BDI), anxiety with the Beck Anxiety Inventory (BAI), pain centralization with the Centrality of Pain Scale (COPS), pain catastrophization with the Pain Catastrophizing Scale (PCS), and FMS severity with the Fibromyalgia Impact Questionnaire (FIQ). Two separate hierarchical linear regression analyses were performed to determine whether there was a significant association between disease severity and the assessed psychosocial factors.</div></div><div><h3>Results</h3><div>The study was completed with a total of 48 FMS patients (mean age 49.54<!--> <!-->±<!--> <!-->8.28 years). FIQ score was moderately correlated with COPS score (<em>r</em><sub>Spearman</sub> <!-->=<!--> <!-->0.670, <em>p</em> <!--><<!--> <!-->0.001) and PCS score (<em>r</em><sub>Spearman</sub> <!-->=<!--> <!-->0.663, <em>p</em> <!--><<!--> <!-->0.001). In the logistic regression model, COPS and PCS scores were significant predictors of FIQ score. The predictive variables explained 43.7% of the variation in FIQ score.</div></div><div><h3>Conclusion</h3><div>This study showed that pain centralization and catastrophization can be considered indicators of disease severity in FMS. The results suggest that routine assessment of pain centralization and pain catastrophizing behaviors in individuals with FMS is needed and that cognitive behavioral therapy approaches may be beneficial in reducing disease severity.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 5","pages":"Article 501893"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144563656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01DOI: 10.1016/j.reumae.2025.501895
Alejandro Balsa , Daniel Seoane-Mato , Marta Domínguez-Álvaro , Mercedes Alperi , Virginia Ruiz-Esquide , Javier Bachiller-Corral , Federico Díaz-González , on behalf of the Remission-RA Study group
Background and objective
The SUMAR project established a definition for remission that includes the patient's perspective (global assessment of pain and HAQ) in the definition of remission in rheumatoid arthritis (RA). This new definition needs to be assessed on clinical practice. The main objective of the RA-Remission study is to estimate the proportion of patients in sustained remission according to SUMAR definition through 2-year follow-up, among patients in SUMAR remission at baseline. This manuscript describes the objectives and methodology of the study.
Materials and methods
This is a longitudinal, prospective, observational and multicentre study, involving 10 centres. Patients with RA who have achieved clinical remission in accordance to their attending rheumatologist clinical judgement within the last 6 months will be included. Follow-up visits will take place at 3, 6, 12, 12, 18 and 24 months. Ultrasound assessment of the power Doppler (PD) signal for 30 joints and 6 tendon regions will be performed at each participating centre by an expert blinded to all other study findings. Definitions of remission according to SUMAR, PD and activity indices will be used. Sustained remission will be considered for each of the definitions when the patient in remission at the baseline visit maintains it during all follow-up visits. To estimate the proportion of patients maintaining remission at two years with an accuracy of at least 6%, 180 patients will need to be recruited.
Discussion and conclusions
The main strength of the design is the use of ultrasound assessment as the gold standard for assessing inflammatory activity.
{"title":"Study of the impact of the inclusion of global pain and functional capacity assessment in the definition of remission and its maintenance for rheumatoid arthritis. Aims and methodology","authors":"Alejandro Balsa , Daniel Seoane-Mato , Marta Domínguez-Álvaro , Mercedes Alperi , Virginia Ruiz-Esquide , Javier Bachiller-Corral , Federico Díaz-González , on behalf of the Remission-RA Study group","doi":"10.1016/j.reumae.2025.501895","DOIUrl":"10.1016/j.reumae.2025.501895","url":null,"abstract":"<div><h3>Background and objective</h3><div>The SUMAR project established a definition for remission that includes the patient's perspective (global assessment of pain and HAQ) in the definition of remission in rheumatoid arthritis (RA). This new definition needs to be assessed on clinical practice. The main objective of the RA-Remission study is to estimate the proportion of patients in sustained remission according to SUMAR definition through 2-year follow-up, among patients in SUMAR remission at baseline. This manuscript describes the objectives and methodology of the study.</div></div><div><h3>Materials and methods</h3><div>This is a longitudinal, prospective, observational and multicentre study, involving 10 centres. Patients with RA who have achieved clinical remission in accordance to their attending rheumatologist clinical judgement within the last 6 months will be included. Follow-up visits will take place at 3, 6, 12, 12, 18 and 24 months. Ultrasound assessment of the power Doppler (PD) signal for 30 joints and 6 tendon regions will be performed at each participating centre by an expert blinded to all other study findings. Definitions of remission according to SUMAR, PD and activity indices will be used. Sustained remission will be considered for each of the definitions when the patient in remission at the baseline visit maintains it during all follow-up visits. To estimate the proportion of patients maintaining remission at two years with an accuracy of at least 6%, 180 patients will need to be recruited.</div></div><div><h3>Discussion and conclusions</h3><div>The main strength of the design is the use of ultrasound assessment as the gold standard for assessing inflammatory activity.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 5","pages":"Article 501895"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144532173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01DOI: 10.1016/j.reumae.2025.501852
Pablo Martínez Calabuig , Jorge Juan Fragío Gil , Roxana González Mazarío , Laura Salvador Maicas , Mireia Lucía Sanmartín Martínez , Antonio Sierra Rivera , Laura Abenza Barberá , María Cristina Sabater Abad , Francesc Puchades Gimeno , Inmaculada Castelló Miralles , Amalia Rueda Cid , Cristina Campos Fernández , on behalf of the HGUV IgG4-Related Disease Working Group
Background and objective
IgG4-related disease (IgG4-RD) is a systemic, immune-mediated, fibro-inflammatory condition with an uncertain etiology and pathophysiology that can affect multiple organs, presenting common clinical, radiological, and serological features. Although the disease is associated with IgG4, serum levels are not elevated in all patients and have also been described in other diseases. The aim of this study is to evaluate the clinical utility of elevated serum IgG4 as a screening marker in the suspicion of IgG4-related disease.
Materials and methods
A retrospective single-center study was conducted, analysing serological IgG4 test requests from electronic medical records of patients ordered by various hospital departments from January 2010 to June 2023. Only those with elevated IgG4 levels were included in the analysis. Additionally, demographic data and final diagnoses, including those with IgG4-RD, were collected.
Results
A total of 2288 test requests were reviewed, of which 247 showed elevated IgG4 levels (181 after excluding duplicates). Among the patients with elevated IgG4, only 11 met the criteria for IgG4-RD based on the 2011 Umehara-Okazaki classification and its 2020 update. However, only 6 patients (3.31%) met the more recent 2019 ACR/EULAR classification criteria for IgG4-RD. In the remaining patients with elevated IgG4, the most common diagnoses were respiratory diseases, such as COPD and asthma, followed by systemic autoimmune diseases, primarily SLE, RA, and EGPA. Elevated IgG4 levels were also observed in malignant neoplasms, predominantly lung and hematologic cancers.
Conclusions
Our study highlights that elevated IgG4 levels are not exclusive to IgG4-RD and can also be observed in various respiratory diseases (e.g., COPD), autoimmune diseases (e.g., SLE and RA), and neoplasms (e.g., lung cancer).
{"title":"Evaluation of serum IgG4 levels as a screening tool for IgG4-related disease: Data from a retrospective study","authors":"Pablo Martínez Calabuig , Jorge Juan Fragío Gil , Roxana González Mazarío , Laura Salvador Maicas , Mireia Lucía Sanmartín Martínez , Antonio Sierra Rivera , Laura Abenza Barberá , María Cristina Sabater Abad , Francesc Puchades Gimeno , Inmaculada Castelló Miralles , Amalia Rueda Cid , Cristina Campos Fernández , on behalf of the HGUV IgG4-Related Disease Working Group","doi":"10.1016/j.reumae.2025.501852","DOIUrl":"10.1016/j.reumae.2025.501852","url":null,"abstract":"<div><h3>Background and objective</h3><div>IgG4-related disease (IgG4-RD) is a systemic, immune-mediated, fibro-inflammatory condition with an uncertain etiology and pathophysiology that can affect multiple organs, presenting common clinical, radiological, and serological features. Although the disease is associated with IgG4, serum levels are not elevated in all patients and have also been described in other diseases. The aim of this study is to evaluate the clinical utility of elevated serum IgG4 as a screening marker in the suspicion of IgG4-related disease.</div></div><div><h3>Materials and methods</h3><div>A retrospective single-center study was conducted, analysing serological IgG4 test requests from electronic medical records of patients ordered by various hospital departments from January 2010 to June 2023. Only those with elevated IgG4 levels were included in the analysis. Additionally, demographic data and final diagnoses, including those with IgG4-RD, were collected.</div></div><div><h3>Results</h3><div>A total of 2288 test requests were reviewed, of which 247 showed elevated IgG4 levels (181 after excluding duplicates). Among the patients with elevated IgG4, only 11 met the criteria for IgG4-RD based on the 2011 Umehara-Okazaki classification and its 2020 update. However, only 6 patients (3.31%) met the more recent 2019 ACR/EULAR classification criteria for IgG4-RD. In the remaining patients with elevated IgG4, the most common diagnoses were respiratory diseases, such as COPD and asthma, followed by systemic autoimmune diseases, primarily SLE, RA, and EGPA. Elevated IgG4 levels were also observed in malignant neoplasms, predominantly lung and hematologic cancers.</div></div><div><h3>Conclusions</h3><div>Our study highlights that elevated IgG4 levels are not exclusive to IgG4-RD and can also be observed in various respiratory diseases (e.g., COPD), autoimmune diseases (e.g., SLE and RA), and neoplasms (e.g., lung cancer).</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 4","pages":"Article 501852"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144096600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01DOI: 10.1016/j.reumae.2025.501847
Fernando Canillas, Marta Canillas
Raoul Dufy was born in 1877 in the city of Le Havre, France. He showed an early interest in painting and attended the École des Beaux Arts in Paris, where he was influenced by Impressionism and later by Fauvism and Cubism. He achieved a style of his own, marked by colour. His paintings depicted modern life, often with bright colours and energetic scenes of urban and social life. In 1935, he developed severe rheumatoid arthritis, which affected his hands and joints. Despite this, he continued to create art until his death. He underwent numerous medical treatments of the time. In 1950, he was invited to the United States to participate in initial ACTH and cortisone therapies and achieved a significant improvement. He returned to France, but died in 1953 at the age of 76 from an intestinal haemorrhage. His artistic legacy and his strength to face this disease are an inspiration for the future.
拉乌尔·杜菲1877年出生于法国勒阿弗尔。他表现出对绘画的早期兴趣，并参加了École des Beaux Arts在巴黎，在那里他受到印象派，后来野兽派和立体派的影响。他形成了自己的风格，以色彩为标志。他的画描绘了现代生活，经常用明亮的色彩和充满活力的城市和社会生活场景。1935年，他患上了严重的类风湿性关节炎，影响了他的手和关节。尽管如此，他仍然继续创作艺术，直到他去世。他当时接受了多次治疗。1950年应邀到美国参加ACTH和可的松的初始治疗，并取得了显著的改善。他回到法国，但在1953年死于肠道出血，享年76岁。他的艺术遗产和他面对这种疾病的力量是对未来的鼓舞。
{"title":"Raoul Dufy: Color and resilience in the fight against rheumatoid arthritis","authors":"Fernando Canillas, Marta Canillas","doi":"10.1016/j.reumae.2025.501847","DOIUrl":"10.1016/j.reumae.2025.501847","url":null,"abstract":"<div><div>Raoul Dufy was born in 1877 in the city of Le Havre, France. He showed an early interest in painting and attended the École des Beaux Arts in Paris, where he was influenced by Impressionism and later by Fauvism and Cubism. He achieved a style of his own, marked by colour. His paintings depicted modern life, often with bright colours and energetic scenes of urban and social life. In 1935, he developed severe rheumatoid arthritis, which affected his hands and joints. Despite this, he continued to create art until his death. He underwent numerous medical treatments of the time. In 1950, he was invited to the United States to participate in initial ACTH and cortisone therapies and achieved a significant improvement. He returned to France, but died in 1953 at the age of 76 from an intestinal haemorrhage. His artistic legacy and his strength to face this disease are an inspiration for the future.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 4","pages":"Article 501847"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01DOI: 10.1016/j.reumae.2025.501851
Benitez Cristian Alejandro , Gomez Ramiro Adrián , Peón Claudia , Alfaro María Agustina , Federico Andrea , Klimovsky Ezequiel , Gamba María Julieta
<div><h3>Objective</h3><div>To correlate ΔRDW and ΔVCM (baseline and week 12) with the number of patients achieving remission or low disease activity by CDAI at week 24 after initiating MTX.</div></div><div><h3>Materials and methods</h3><div>Retro-prospective, analytical, and observational study in consecutive adult patients diagnosed with RA (ACR/EULAR 2010). Demographic data, clinical characteristics, personal history, initiated treatments, and VCM (fL) and RDW (%) at weeks 0, 4, 12, and 24 were evaluated. Safety data was recorded. Statistical analysis: descriptive analysis, Chi<sup>2</sup> test or Fisher's exact test; Student's <em>T</em>-test or Mann–Whitney; and ANOVA or Kruskal–Wallis. Lineal and/or multiple logistic regression.</div></div><div><h3>Results</h3><div>139 patients were included, of whom 109 completed the study requirements. 83.5% were women, median age (m) 50 years (IQR 39–60), with a median disease duration of 12 months (IQR 0–78). In the per-protocol analysis of 109 patients, the m ΔRDW between baseline and week 12 was 0.8 (IQR 0–2.4), and the m ΔVCM was 2.0 (IQR 0.1–4.4). No correlation was found between ΔRDW and CDAI at week 24 (Rho<!--> <!-->=<!--> <!-->−0.08; <em>p</em> <!-->=<!--> <!-->0.416), but a statistically significant correlation was found between ΔVCM and CDAI at week 24 (Rho<!--> <!-->=<!--> <!-->−0.190; <em>p</em> <!-->=<!--> <!-->0.048).</div><div>Results were analyzed by intention to treat for 139 patients. Between baseline and week 12, a m ΔRDW of 0.8 (IQR 0–2.4) and a m ΔVCM of 2.2 (IQR 0.2–4.5) were recorded. No correlation was found between ΔRDW and CDAI at week 24 (Rho<!--> <!-->=<!--> <!-->−0.073; <em>p</em> <!-->=<!--> <!-->0.433), but a statistically significant correlation was found between ΔVCM and CDAI at week 24 (Rho<!--> <!-->=<!--> <!-->−0.217; <em>p</em> <!-->=<!--> <!-->0.018). 64.2%, 39.4%, and 15.6% of patients achieved CDAI 50/70/85 responses at week 12, respectively, with no significant changes at week 24. Univariate and multivariate analysis identified that the only factor significantly associated with achieving CDAI 50 at week 24 was achieving such a response at week 12 (<em>p</em> <!-->=<!--> <!-->0.001).</div><div>Safety evaluation showed that 68 patients (48.9%) experienced adverse events, with 20 events (14.4%) related to MTX. Only 5 (3.6%) were considered serious adverse events, all of them unrelated to treatment.</div></div><div><h3>Conclusions</h3><div>This study revealed that an increase in red cell distribution width (RDW) and mean corpuscular volume (VCM) was associated with the initiation of MTX treatment. However, only a significant correlation was found between the change in VCM and RA activity measured by CDAI at week 24. Although ΔRDW did not show a significant association with RA activity, ΔVCM negatively correlated with CDAI at week 24. Additionally, a significant percentage of patients achieved a positive response at week 12, but there were no significant changes at we
{"title":"Mean corpuscular volume and red cell distribution width as predictors of methotrexate response in RA patients","authors":"Benitez Cristian Alejandro , Gomez Ramiro Adrián , Peón Claudia , Alfaro María Agustina , Federico Andrea , Klimovsky Ezequiel , Gamba María Julieta","doi":"10.1016/j.reumae.2025.501851","DOIUrl":"10.1016/j.reumae.2025.501851","url":null,"abstract":"<div><h3>Objective</h3><div>To correlate ΔRDW and ΔVCM (baseline and week 12) with the number of patients achieving remission or low disease activity by CDAI at week 24 after initiating MTX.</div></div><div><h3>Materials and methods</h3><div>Retro-prospective, analytical, and observational study in consecutive adult patients diagnosed with RA (ACR/EULAR 2010). Demographic data, clinical characteristics, personal history, initiated treatments, and VCM (fL) and RDW (%) at weeks 0, 4, 12, and 24 were evaluated. Safety data was recorded. Statistical analysis: descriptive analysis, Chi<sup>2</sup> test or Fisher's exact test; Student's <em>T</em>-test or Mann–Whitney; and ANOVA or Kruskal–Wallis. Lineal and/or multiple logistic regression.</div></div><div><h3>Results</h3><div>139 patients were included, of whom 109 completed the study requirements. 83.5% were women, median age (m) 50 years (IQR 39–60), with a median disease duration of 12 months (IQR 0–78). In the per-protocol analysis of 109 patients, the m ΔRDW between baseline and week 12 was 0.8 (IQR 0–2.4), and the m ΔVCM was 2.0 (IQR 0.1–4.4). No correlation was found between ΔRDW and CDAI at week 24 (Rho<!--> <!-->=<!--> <!-->−0.08; <em>p</em> <!-->=<!--> <!-->0.416), but a statistically significant correlation was found between ΔVCM and CDAI at week 24 (Rho<!--> <!-->=<!--> <!-->−0.190; <em>p</em> <!-->=<!--> <!-->0.048).</div><div>Results were analyzed by intention to treat for 139 patients. Between baseline and week 12, a m ΔRDW of 0.8 (IQR 0–2.4) and a m ΔVCM of 2.2 (IQR 0.2–4.5) were recorded. No correlation was found between ΔRDW and CDAI at week 24 (Rho<!--> <!-->=<!--> <!-->−0.073; <em>p</em> <!-->=<!--> <!-->0.433), but a statistically significant correlation was found between ΔVCM and CDAI at week 24 (Rho<!--> <!-->=<!--> <!-->−0.217; <em>p</em> <!-->=<!--> <!-->0.018). 64.2%, 39.4%, and 15.6% of patients achieved CDAI 50/70/85 responses at week 12, respectively, with no significant changes at week 24. Univariate and multivariate analysis identified that the only factor significantly associated with achieving CDAI 50 at week 24 was achieving such a response at week 12 (<em>p</em> <!-->=<!--> <!-->0.001).</div><div>Safety evaluation showed that 68 patients (48.9%) experienced adverse events, with 20 events (14.4%) related to MTX. Only 5 (3.6%) were considered serious adverse events, all of them unrelated to treatment.</div></div><div><h3>Conclusions</h3><div>This study revealed that an increase in red cell distribution width (RDW) and mean corpuscular volume (VCM) was associated with the initiation of MTX treatment. However, only a significant correlation was found between the change in VCM and RA activity measured by CDAI at week 24. Although ΔRDW did not show a significant association with RA activity, ΔVCM negatively correlated with CDAI at week 24. Additionally, a significant percentage of patients achieved a positive response at week 12, but there were no significant changes at we","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 4","pages":"Article 501851"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144238312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01DOI: 10.1016/j.reumae.2025.501857
Leonardo F. Freitas , Márcio Luís Duarte , Kevin J. Abrams
{"title":"Novel imaging findings of masticatory muscle edema in dermatomyositis associated with ovarian cancer: A case report","authors":"Leonardo F. Freitas , Márcio Luís Duarte , Kevin J. Abrams","doi":"10.1016/j.reumae.2025.501857","DOIUrl":"10.1016/j.reumae.2025.501857","url":null,"abstract":"","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 4","pages":"Article 501857"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144239764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sarcoidosis is a multisystemic granulomatous disease of uncertain etiology. Several drugs have been linked to the development of sarcoidosis or systemic granulomatous reactions indistinguishable from this disease. We present the clinical case of a patient diagnosed with breast cancer and undergoing treatment with capecitabine who, after developing systemic and musculoskeletal symptoms, was ultimately diagnosed with capecitabine-induced sarcoidosis.
{"title":"Capecitabine-induced sarcoidosis in an oncology patient: Clinical presentation with arthritis","authors":"Yedra Usón-Rodríguez , Fátima Mocha-Campillo , Maialen Guerrero-Gómez , Juan Lao-Romera , Marina Soledad Moreno-García","doi":"10.1016/j.reumae.2025.501870","DOIUrl":"10.1016/j.reumae.2025.501870","url":null,"abstract":"<div><div>Sarcoidosis is a multisystemic granulomatous disease of uncertain etiology. Several drugs have been linked to the development of sarcoidosis or systemic granulomatous reactions indistinguishable from this disease. We present the clinical case of a patient diagnosed with breast cancer and undergoing treatment with capecitabine who, after developing systemic and musculoskeletal symptoms, was ultimately diagnosed with capecitabine-induced sarcoidosis.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 4","pages":"Article 501870"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01DOI: 10.1016/j.reumae.2025.501845
Carlota Navarro-Joven , María Alonso de Francisco , Margarita Pich-Aguilera Blasco , Rita María Cabeza Martínez , José Luis Andreu Sánchez , Hildegarda Godoy-Tundidor
Rowell’s syndrome (RS) is an unusual form of subacute cutaneous lupus. We present the case of a male patient with chronic RS who exhibits a remarkable response to anifrolumab.
{"title":"Use of anifrolumab in a patient with chronic multirefractory Rowell’s syndrome","authors":"Carlota Navarro-Joven , María Alonso de Francisco , Margarita Pich-Aguilera Blasco , Rita María Cabeza Martínez , José Luis Andreu Sánchez , Hildegarda Godoy-Tundidor","doi":"10.1016/j.reumae.2025.501845","DOIUrl":"10.1016/j.reumae.2025.501845","url":null,"abstract":"<div><div>Rowell’s syndrome (RS) is an unusual form of subacute cutaneous lupus. We present the case of a male patient with chronic RS who exhibits a remarkable response to anifrolumab.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 4","pages":"Article 501845"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号